^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | sacituzumab tirumotecan (MK-2870) (Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
380MO - SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): Results from a phase I/II, single-arm, basket trial
Published date:
10/16/2023
Excerpt:
The ORR was 36.8% (14/38, 12 confirmed PR and 2 unconfirmed PR) and DCR was 89.5%, median DoR was 7.4 mo (range, 4.2 to 14.9+), 6-mo DoR rate was 80%. Median PFS was 11.1 mo (95% Cl: 5.4, 13.1), and 6-mo PFS rate was 61.2%...SKB264 at 5 mg/kg demonstrates a manageable safety profile and promising antitumor activity in pts with pre-treated HR+/HER2- mBC.
Trial ID:
